Mosaic Family Wealth Partners LLC Trims Position in Eli Lilly and Company (NYSE:LLY)

Mosaic Family Wealth Partners LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,722 shares of the company’s stock after selling 156 shares during the quarter. Mosaic Family Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $1,340,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in LLY. Independent Advisor Alliance raised its position in shares of Eli Lilly and Company by 1.7% in the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after buying an additional 544 shares during the period. Apexium Financial LP raised its position in shares of Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after buying an additional 10,842 shares during the period. Terril Brothers Inc. raised its position in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares during the period. Capital Planning LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth $262,000. Finally, Hartline Investment Corp raised its position in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after buying an additional 248 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares in the company, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on LLY shares. Berenberg Bank increased their price target on Eli Lilly and Company from $850.00 to $1,000.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Barclays increased their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,001.00 price target on shares of Eli Lilly and Company in a report on Wednesday, July 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Wednesday, July 24th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $858.72.

Eli Lilly and Company Stock Down 3.4 %

NYSE:LLY traded down $27.98 during mid-day trading on Friday, reaching $804.46. The stock had a trading volume of 3,515,933 shares, compared to its average volume of 3,316,491. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock’s 50 day simple moving average is $870.80 and its two-hundred day simple moving average is $788.92. Eli Lilly and Company has a 1-year low of $446.89 and a 1-year high of $966.10. The company has a market capitalization of $764.57 billion, a price-to-earnings ratio of 118.48, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the company posted $1.62 earnings per share. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 13.79 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.